Literature DB >> 19224517

Acute colonic pseudo-obstruction.

R De Giorgio1, C H Knowles.   

Abstract

BACKGROUND: Acute colonic pseudo-obstruction is characterized by clinical and radiological evidence of acute large bowel obstruction in the absence of a mechanical cause. The condition usually affects elderly people with underlying co-morbidities, and early recognition and appropriate management are essential to reduce the occurrence of life-threatening complications.
METHODS: A part-systematic review was conducted. This was based on key publications focusing on advances in management. RESULTS AND
CONCLUSIONS: Although acute colonic dilatation has been suggested to result from a functional imbalance in autonomic nerve supply, there is little direct evidence for this. Other aetiologies derived from the evolving field of neurogastroenterology remain underexplored. The rationale of treatment is to achieve prompt and effective colonic decompression. Initial management includes supportive interventions that may be followed by pharmacological therapy. Controlled clinical trials have shown that the acetylcholinesterase inhibitor neostigmine is an effective treatment with initial response rates of 60-90 per cent; other drugs for use in this area are in evolution. Colonoscopic decompression is successful in approximately 80 per cent of patients, with other minimally invasive strategies continuing to be developed. Surgery has thus become largely limited to those in whom complications occur. A contemporary management algorithm is provided on this basis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224517     DOI: 10.1002/bjs.6480

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  25 in total

1.  The effect of erythromycin on gastrointestinal motility in subtotal gastrectomized patients.

Authors:  A-Lan Lee; Choong-Bai Kim
Journal:  J Korean Surg Soc       Date:  2012-02-27

Review 2.  Endoscopy in the diagnosis and management of motility disorders.

Authors:  Yael Kopelman; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-02-01       Impact factor: 3.199

Review 3.  Ileus in Adults.

Authors:  Tim O Vilz; Burkhard Stoffels; Christian Strassburg; Hans H Schild; Jörg C Kalff
Journal:  Dtsch Arztebl Int       Date:  2017-07-24       Impact factor: 5.594

Review 4.  [Acute colonic pseudo-obstruction: Ogilvie syndrome].

Authors:  J Keller; P Layer
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-09-23       Impact factor: 0.840

5.  Neostigmine treatment protocols applied in acute colonic pseudo-obstruction disease: A retrospective comparative study.

Authors:  Ömür İlban; Faruk Çiçekçi; Jale Bengi Çelik; Mehmet Ali Baş; Ateş Duman
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

6.  Giant colonic volvulus due to colonic pseudo-obstruction.

Authors:  Kerem Karaman; Alpaslan Tanoglu; Yavuz Beyazit; Ismet Han
Journal:  BMJ Case Rep       Date:  2015-02-25

7.  Mangiferin ameliorates the intestinal inflammatory response and the impaired gastrointestinal motility in mouse model of postoperative ileus.

Authors:  Talita Cavalcante Morais; Bruno Rodrigues Arruda; Hebert de Sousa Magalhães; Maria Teresa Salles Trevisan; Daniel de Araújo Viana; Vietla Satyanarayana Rao; Flavia Almeida Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-05       Impact factor: 3.000

8.  Pelvic surgeons be aware: Ogilvie's syndrome (a case report).

Authors:  Amy George; Allison Hensley; Douglass Hale
Journal:  Int Urogynecol J       Date:  2012-07-03       Impact factor: 2.894

9.  Advances and challenges in the management of acute colonic pseudo-obstruction (ogilvie syndrome).

Authors:  Arpana Jain; H David Vargas
Journal:  Clin Colon Rectal Surg       Date:  2012-03

10.  Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility.

Authors:  J Broad; V W S Kung; G Boundouki; Q Aziz; J H De Maeyer; C H Knowles; G J Sanger
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.